TMEM214

Across TCGA pan-cancer cohorts, TMEM214 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM214 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM214 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM214 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LUAD are the cancer types where TMEM214 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.670	0.955	.002	60	view →
PDAC	DFS	Median	All	0.621	0.820	.005	18	view →
LUAD	DFS	Median	All	0.899	1.000	.027	4	view →
LSCC	DFS	Tertile	II,III,IV	0.702	0.927	.023	4	view →
HNSC	DFS	Tertile	III,IV	0.899	1.000	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM214–CCRCC (OS)

Open the CCRCC breakdown →